, which Kontopoulos hopes will hit their strides and deliver consistent financial growth in just a year or two.The buzzy biotech Perlara got into Y Combinator and raised $10 million from investors like Mark Cuban before things went south. Its founder shares the key lesson he learned from the failure.
In the last bucket are cheaper"high risk, high reward" companies, which could be poised to move into the middle bucket — but could also fail. How Kontopoulos's strategy will perform is still a work in progress, since Kontopoulos took over less than a year ago. The fund has done somewhat better than the Nasdaq Biotechnology Index over the past year, with a total return of 3.5%. The fund charges ordinary investors an expense ratio of more than 1%, which can cut into returns.two out of five stars by Morningstar as of the end of March, a ranking that's based on past performance.
Fidelityiscriminal